Urogen Pharma
URGN Healthcare Biotechnology
Urogen Pharma’s revenue for fiscal 2025 (year ended December 2025) was $109.8 million, up 21.4% from fiscal 2024. In the quarter to June 2026, revenue grew 199.2%, EPS grew 73.3%, free cash flow grew 17.3% and total debt rose 56.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow URGN
Urogen Pharma (URGN) EV/Sales
As of 16 October 2026, Urogen Pharma (URGN) trades at a EV/Sales of 9.7×. Over the past ten years it has ranged from 0.0× (March 2018) to 858× (December 2019); the current reading is higher than 58% of that period. That is in line with the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 10.3× | 173.35% |
| FY2024 | 3.8× | (21.96%) |
| FY2023 | 4.8× | 60.32% |
| FY2022 | 3.0× | 18.05% |
| FY2021 | 2.6× | (89.63%) |
| FY2020 | 24.6× | (96.97%) |
| FY2019 | 812× | 58.82% |
| FY2018 | 511× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 10.3× | 51.69% |
| Mar 2026 | 6.8× | (34.33%) |
| Dec 2025 | 10.3× | 4.37% |
| Sep 2025 | 9.9× | 50.36% |
| 29 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BHVN Biohaven Ltd. compare | 1.6× |
| VIR Vir Biotechnology, Inc. compare | 3.7× |
| MRVI Maravai LifeSciences Holdings, Inc. compare | 5.3× |
| URGN Urogen Pharma | 9.7× |
| SEPN Septerna, Inc. compare | 12.7× |
| XNCR Xencor, Inc. compare | 13.4× |
| PVLA Palvella Therapeutics, Inc. compare | 35.6× |
| ZYME Zymeworks Inc. compare | 42.0× |
| MESO Mesoblast Limited compare | 137× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)